Knyga 2008 09_2 be EndNote.indd - Saulius Čaplinskas

Atsako į AIDS ir narkomaniją kontroversijos
opportunistic infections, Boston, Massachusetts, February 22-25,
2005: abstract 167. Boston, Massachusetts, Alexandria, VA: Foundation
for Retrovirology and Human Health. 2005: 125.
263 Chesney MA. Factors affecting adherence to antiretroviral therapy.
Clin Infect Dis 2000; 30 (2 Suppl): 171-6.
264 Lucas GM, Chaisson RE, Moore RD, et al. Highly active antiretroviral
therapy in a large urban clinic: risk factors for virologic failure and
adverse drug reactions. Ann Intern Med 1999; 131 (2): 81-7.
265 Valdez H, Lederman MM, Woolley I, et al. Human immunodeficiency
virus 1 protease inhibitors in clinical practice: predictors of virological
outcome . Arch Intern Med 1999; 159 (15): 1771-6.
266 Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor
therapy and outcomes in patients with HIV infection. Ann Intern Med
2000; 133 (1): 21-30.
267 Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B
infection: Lessons learned from treating HIV infected patients. Journal
of Hepatology 1999;30:536-550.
268 Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis
P, Danner SA, Mulder J, Loveday C, Christopherson C, et al. Rapid
changes in human immunodeficiency virus type 1 RNA load and
appearance of drug-resistant virus populations in persons treated
with lamivudine (3TC). J Infect Dis 1995;171:1411-9.
269 Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey
R, Ruedy J, Hirst HM, Cammack N, Cameron J, et al. Development of
HIV-1 resistance to (-)2’-deoxy-3’-thiacytidine in patients with AIDS or
advanced AIDS-related complex. Aids 1995;9:351-7.
270 Ho D, Toyoshima T, Mo H, Kempf D, Norbeck D, Chen Cea.
Characterisation of human immunodeficiency virus type 1 variants
with increased resistance to a C2-symmetic protease inhibitor. J Virol
1994;68:2016-2020.
271 Klimkait T., Vernazza P. Adherence and Resistance. Ther Umsch.2004.
oct;61(10):631-4.
272 Bangsberg D.R. Preventing HIV antiretroviral resistance through
better monitoring of treatment adherence. J Infect Dis. 2008 May
15;197 Suppl 3:S272-8.
273 Smith R. J. Adherence to antiretroviral HIV drugs: how many doses
can you miss before resistance merges. Proc Biol Sci. 2006 Mar
7;273(1586):617-24.
274 Caplinskas S., Loukachov V., Gasich E., Gilyazova A., Caplinskiene
I. Distinct HIV-1 strains circulating in different risk groups and the
absence of new infections by drug-resistant strains in Lithuania. PLOS
ONE (in press).
275 Ickovics JR, Meisler AW. Adherence in AIDS clinical trials : a framework
for clinical research and clinical care. J Clin Epidemiol 1997; 50 (4):
385-91.
276 Palella FJJr, Delaney KM, Moorman AC, et al. Declining morbidity and
mortality among patients with advanced human immunodeficiency
virus infection. HIV Outpatient study investigators. N Engl J Med 1998;
338 (13): 853-60.
277 Hsu LC, Vittinghoff E, Katz MH, et al. Predictors of use of highly active
antiretroviral therapy (HAART) among persons with AIDS in San
Francisco, 1996-1999. J Acquir Immune Defic Syndr 2001; 28 (4):
345-50.
278 Fairfield KM, Libman H, Davis RB, Eisenberg DM. Delays in protease
inhibitor use in clinical practice. J Gen Intern Med 1999; 14 (7): 395-
401.
279 Cook JA, Cohen MH, Grey D, et al. Use of highly active antiretroviral
therapy in a cohort of HIV-seropositive women. Am J Public Healt
2002; 92 (91): 82-7.
280 Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of
HIV-infected adults in the United States: results from the HIV cost and
services utilization study. JAMA 1999; 281 (24): 2305-15.
281 Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups
to antiretroviral therapy among persons in care for HIV disease in the
United States. HCSUS consortium. HIV cost and services utilization
study. Health Serv Res 2000; 35 (2): 389-416.
282 Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free
antiretroviral therapy in injection drug users. JAMA 1998; 280 (6):
547-9.
283 Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender
differences in starting protease inhibitors, HAART, and disease
progression despite equal access to care. J Acquir Immune Defic
Syndr 2000; 24 (5): 475-82.
284 Anderson KH, Mitchell JM. Differential access in the receipt of
antiretroviral drugs for the treatment of AIDS and its implications for
survival. Arch Intern Med 2000; 160 (2): 3114-20.
285 Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and
mortality among patients with advanced human immunodeficiency
virus infection. HIV Outpatient study investigators. N Engl J Med 1998;
338 (13): 853-60.
286 Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral
therapy (HAART) not prescribed or discontinued Swiss HIV cohort
study. J Acquir Immune Defic Syndr 1999; 21 (2): 114-19.
287 Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure
groups in the EuroSIDA Study: starting highly active antiretroviral
therapy (HAART), response to HAART, and survival. J Acquir Immune
Defic Syndr 1999; 22 (4): 369-78.
288 Hsu LC, Vittinghoff E, Katz MH, et al. Predictors of use of highly active
antiretroviral therapy (HAART) among persons with AIDS in San
Francisco, 1996-1999. J Acquir Immune Defic Syndr 2001; 28 (4):
345-50.
289 Fairfield KM, Libman H, Davis RB, Eisenberg DM. Delays in protease inhibitor
use in clinical practice. J Gen Intern Med 1999; 14 (7): 395-401.
290 Bing EG, Kilbourne AM, Brooks RA, et al. Protease inhibitor use among
a community sample of people with HIV disease. J Acquir Immune
Defic Syndr 1999; 20 (5): 474-80.
291 Chesney MA. Factors affecting adherence to antiretroviral therapy.
Clin Infect Dis 2000; 30 (2 Suppl): 171-6.
292 Max B, Sherer R. Management of the adverse effects of antiretroviral
therapy and medication adherence. Clin Infect Dis. 2000; 30 (2 Suppl):
96-116.
293 Lucas G, Gebo K, Chaisson RE, et al. Longitudinal assessment of the
effects of drug and alcohol abuse on HIV treatment. In: Program and
abstracts of the 9th conference on retroviruses and opportunistic
infections, Washington, February 24-28, 2002: abstract 547-T. Seatle,
Washington, Alexandria, VA: Foundation for etrovirology and Human
Health, 2002.
294 Guidelines for the use of antiretroviral agents in HIV-infected adults
and adolescents / Department of health and human services and the
Henry J. Kaiser family foundation. Updated February 2002. Accessed
October 7, 2002. Prieiga per internetą:
295 Petersen ML, Van der Laan MJ, Napravnik S, et al. Long-term consequences
of the delay between virologic failure of highly active
antiretroviral therapy and regimen modification. AIDS 2008; 22 (16):
2097-106.
296 Turner BJ, Fleishman JA, Wenger N, et al. Effects of drug abuse and
mental disorders on use and type of antiretroviral therapy in HIVinfected
persons. J Gen Intern Med 2001; 16 (9): 625-33.
297 Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active
antiretroviral therapy among HIV-infected injection drug users. AIDS
2001; 15(13): 1707-15.
298 Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral
therapy on time to AIDS and death in men with known HIV
infection duration. Multicenter AIDS cohort study investigators.
JAMA 1998; 280 (17): 1497-503.
299 Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality
across Europe in patients infected with HIV-1. EuroSIDA study group.
Lancet 1998; 352 (9142): 1725-30.
300 Giordano TP, White A, Clinton Jr, et al. Factors associated with the use
69